Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Spark adds fresh evidence that pioneering gene therapy could be a game changer for patients
9 years ago
R&D
Bristol-Myers reels back in an early-stage cancer drug prospect in $60M Asia deal
9 years ago
R&D
Protocols: Valeant sheds assets, but falls short on consensus; What if voters got a chance to weigh in on your trial?
9 years ago
News Briefing
As gene therapy rivals advance, Biogen moves closer to spinning out hemophilia drugs, R&D
9 years ago
R&D
FDA clears a Phase III path for Biogen’s BACE drug for Alzheimer’s
9 years ago
R&D
Will AbbVie bite? Decision time after Ablynx's rheumatoid arthritis drug fails a key study
9 years ago
R&D
Now a two-time loser, AstraZeneca’s hopes for selumetinib dwindle after another PhIII flop
9 years ago
R&D
Racing past a wounded Juno, Kite aims to file lead CAR-T for OK by end of 2016
9 years ago
R&D
Protocols: Allergan disses giant leaps, concentrates on stepping stones; AstraZeneca also gets a boost from ...
9 years ago
News Briefing
Acetylon can say goodbye to buyout and a $1B-plus in Celgene biobucks
9 years ago
R&D
Novartis's asthma ‘wonder drug’ basks in the bright spotlight of a UK media frenzy
9 years ago
R&D
Little MEI Pharma rockets up on $25M cash injection, deep-pocket partner for PhIII AML cancer study
9 years ago
R&D
Celgene stays focused on protein homeostasis, backs Cleave’s $37M round to fuel early studies
9 years ago
R&D
Allergan, Richter steer past another late-stage pileup with cariprazine
9 years ago
R&D
Protocols: Did Ionis set out to exclude side effects? Merck takes another step forward with Lantus biosimilar
9 years ago
News Briefing
Woodford gets slammed with a brutal set of portfolio hits, as Northwest continues to fester
9 years ago
R&D
Thumbs Up/Thumbs Down: The new buzz in R&D, blockbuster work on a budget and why what’s dead may never die
9 years ago
Bioregnum
Opinion
Bristol-Myers craters after blockbuster checkpoint drug Opdivo fails key lung cancer study
9 years ago
R&D
Gemphire IPO staggers into the market, reaping $30M
9 years ago
R&D
Deaths derail Juno's launch countdown, giving Kite and Novartis the lead
9 years ago
R&D
Pushed by high costs in Cambridge, fast-growing Decibel makes a pioneering leap to Fenway
9 years ago
R&D
Momenta hit with a setback as pancreatic cancer drug flops in PhII
9 years ago
R&D
Regeneron makes a blockbuster case for its PhIII drug pipeline
9 years ago
R&D
BioRegnum: What’s the deal with Biogen?
9 years ago
Bioregnum
Opinion
First page
Previous page
1169
1170
1171
1172
1173
1174
1175
Next page
Last page